<DOC>
	<DOCNO>NCT00384553</DOCNO>
	<brief_summary>This study investigate toxicity efficacy 2 x R-DHAP follow High dose chemotherapy R-TEC autologous stem cell transplantation patient relapse refractory aggressive Non- Hodgkins 's Lymphoma .</brief_summary>
	<brief_title>Risk Adapted Therapy Optimization Patients With Relapsed Refractory Aggressive Non-Hodgkin-Lymphoma</brief_title>
	<detailed_description>Initial Cytoreduction perform DHAP- protocol use dexamethasone , cytarabine cisplatin follow high dose chemotherapy treosulfan , etoposide cisplatin ( TEC ) autologous peripheral blood stem cell transplantation ( aPBSCT ) . In case partial remission second identical high dose chemotherapy aPBSCT follow . Patients primary refractory disease early relapse within 6 month receive allogenous stem cell transplantation . For Patients CD 20 positive B-cell lymphoma chemotherapy regiment DHAP TEC combine rituximab .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>first relapse primary refractory disease aggressive NonHodgkin 's lymphoma stage IIV pretreatment systemic therapy 1865 year age Performance status : ECOG 02 Granulocyte count &gt; 1.5/µm3 , Platelet count &gt; 100/µm3 Creatinine Clearance ≥ 1 ml/sec GPT/GOT ≤ 1.5 x normal ( except tumour relate ) Bilirubine &lt; 22 µmol/l participation another study 3 month study −informed consent Second neoplasia history exist except basalioma squamous epithelium carcinoma skin remove cervical intraepithelial neoplasia CNS involvement lymphoma respiratory Partial global insufficiency cardiac insufficiency ( NYHAStage 34 , EF &lt; 30 % ) severe neurological psychiatric disease pregnancy HIV positivity , active virus hepatitis , bacterial infection − No follow procedure ensure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2006</verification_date>
</DOC>